Sirnaomics Ltd
HKEX:2257
Intrinsic Value
Sirnaomics Ltd. operates as a holding company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of Sirnaomics Ltd.
Fundamental Analysis
Balance Sheet Decomposition
Sirnaomics Ltd
| Current Assets | 74.2m |
| Cash & Short-Term Investments | 57.3m |
| Other Current Assets | 16.9m |
| Non-Current Assets | 49.7m |
| Long-Term Investments | 20.2m |
| PP&E | 27.6m |
| Intangibles | 853k |
| Other Non-Current Assets | 1m |
| Current Liabilities | 17.5m |
| Accounts Payable | 6.4m |
| Accrued Liabilities | 8m |
| Other Current Liabilities | 3.1m |
| Non-Current Liabilities | 23.9m |
| Long-Term Debt | 37.5m |
| Other Non-Current Liabilities | -13.6m |
Earnings Waterfall
Sirnaomics Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-94.1m
USD
|
|
Operating Income
|
-94.1m
USD
|
|
Other Expenses
|
9.7m
USD
|
|
Net Income
|
-84.4m
USD
|
Free Cash Flow Analysis
Sirnaomics Ltd
Profitability Score
Profitability Due Diligence
Sirnaomics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Sirnaomics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Sirnaomics Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Sirnaomics Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Sirnaomics Ltd
According to Wall Street analysts, the average 1-year price target for Sirnaomics Ltd is 43.56 HKD .
Shareholder Return
Price
Sirnaomics Ltd
| Average Annual Return | -7.22% |
| Standard Deviation of Annual Returns | 48.51% |
| Max Drawdown | -94% |
| Market Capitalization | 519.8m HKD |
| Shares Outstanding | 88 544 830 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sirnaomics Ltd. operates as a holding company. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2021-12-30. The firm is engaged in discovering and developing drugs for indications with unmet medical needs and market opportunities. The Company’s product pipeline has broad therapeutic utility across market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. The Company’s targets once selected based on clear scientific rationale, it applies an algorithm based on its understanding of the biochemical mechanisms involved in RNA interference to identify candidate RNA interference (RNAi) trigger sequences against the selected target gene and employ high throughput processes to design, screen and test future pipeline products. The company has five ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in investigational new drug (IND) enabling or advanced preclinical studies.
You don't have any saved screeners yet
